Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials

Medicina Clinica

Volumn 145, Issue 12, 2015, Pages 511-519

  Catalá López, Ferrán ^a,b   Corrales, Inmaculada ^a   De La Fuente Honrubia, César ^a   González Bermejo, Diana ^a   Martín Serrano, Gloria ^a   Montero, Dolores ^a   Saint Gerons, Diego Macías ^a  

^a Division of Pharmacoepidemiology and Pharmacovigilance   (Spain)

^b Fundacion Instituto de Investigacion en Servicios de Salud   (Spain)

Author keywords

Eltrombopag; Meta analysis; Randomized controlled trials; Romiplostim; Thrombocytopenia; Thromboembolism; Thrombosis

Indexed keywords

ELTROMBOPAG; ROMIPLOSTIM; BENZOIC ACID DERIVATIVE; FC RECEPTOR; HEMATOLOGIC AGENT; HYBRID PROTEIN; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ADULT; ARTICLE; DRUG SAFETY; FREQUENCY; HUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; META ANALYSIS; STATISTICAL MODEL;

ADULT; BENZOATES; HEMATOLOGIC AGENTS; HUMANS; HYDRAZINES; MODELS, STATISTICAL; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPOIETIN;

EID: 84952876095     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2015.03.014     Document Type: Article

References (35)

1. S.S. Sekhon, and V. Roy Thrombocytopenia in adults: a practical approach to evaluation and management South Med J 99 2006 491 498
2. R. Stasi, J. Bosworth, E. Rhodes, M.S. Shannon, F. Willis, and E.C. Gordon-Smith Thrombopoietic agents Blood Rev 24 2010 179 190
3. J. de la Rubia, E. Contreras, and J. Del Río-Garma Thrombotic thrombocytopenic purpura Med Clin (Barc) 136 2011 534 540
4. European Medicines Agency Summary of Products Characteristics for Nplate (last update July 2014) Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000942/WC500039537.pdf [accessed December 2014] 2014
5. European Medicines Agency Summary of Products Characteristics for Revolade (last update August 2014) Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001110/WC500089964.pdf [accessed December 2014] 2014
6. G. Molineux, and A. Newland Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside Br J Haematol 150 2010 9 20
7. H.M. Rinder, J.E. Schuster, C.S. Rinder, C. Wang, H.J. Schweidler, and B.R. Smith Correlation of thrombosis with increased platelet turnover in thrombocytosis Blood 91 1998 1288 1294
8. A.I. Schafer Essential thrombocythemia and thrombocytosis M.A. Lichtman, E. Beutler, T.J. Kipps, U. Slegsohn, K. Kaushansky, J.T. Prchal, Williams hematology 7th ed. 2006 McGraw-Hill Medical New York
9. F. Catalá-López, I. Corrales, G. Martín-Serrano, A. Tobías, and G. Calvo Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials Med Clin (Barc) 139 2012 421 429
10. N.H. Afdhal, E.G. Giannini, G. Tayyab, A. Mohsin, J.W. Lee, A. Andriulli, and et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia N Engl J Med 367 2012 716 724
11. N.H. Afdhal, G.M. Dusheiko, E.G. Giannini, P.J. Chen, K.H. Han, A. Mohsin, and et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy Gastroenterology 146 2014 442 452
12. A. Giagounidis, G.J. Mufti, P. Fenaux, M.A. Sekeres, J. Szer, U. Platzbecker, and et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia Cancer 120 2014 1838 1846
13. J.P.T. Higgins, and S. Green Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane handbook for systematic reviews of interventions 5.1.0 [Web document]. The Cochrane Collaboration 2011 Available at: http://handbook.cochrane.org/ [accessed December 2014]
14. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, and et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary Control Clin Trials 17 1996 1 12
15. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, J.P. Ioannidis, and et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 151 2009 W65 W94
16. G. Urrútia, and X. Bonfill PRISMA declaration: a proposal to improve the publication of systematic reviews and meta-analyses Med Clin (Barc) 135 2010 507 511
17. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
18. F. Catalá-López, and A. Tobías Meta-analysis of randomized trials, heterogeneity and prediction intervals Med Clin (Barc) 142 2014 270 274
19. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
20. C.B. Begg, and M. Mazumdar Operating characteristic of a rank correlation test for publication bias Biometrics 50 1994 1088 1091
21. M. Egger, G. Davey, M. Schenider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
22. J.B. Bussel, D.J. Kuter, J.N. George, R. McMillan, L.M. Aledort, G.T. Conklin, and et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP N Engl J Med 355 2006 1672 1681
23. D.J. Kuter, J.B. Bussel, R.M. Lyons, V. Pullarkat, T.B. Gernsheimer, F.M. Senecal, and et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial Lancet 371 2008 395 403
24. T.B. Gernsheimer, J.N. George, L.M. Aledort, M.D. Tarantino, U. Sunkara, D. Matthew Guo, and et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP) J Thromb Haemost 8 2010 1372 1382
25. D.J. Kuter, M. Rummel, R. Boccia, B.G. Macik, I. Pabinger, D. Selleslag, F. Rodeghiero, B.H. Chong, X. Wang, and D.P. Berger Romiplostim or standard of care in patients with immune thrombocytopenia N Engl J Med 363 2010 1889 1899
26. A. Kellum, A. Jagiello-Gruszfeld, I.N. Bondarenko, R. Patwardhan, C. Messam, and Y. Mostafa Kamel A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors Curr Med Res Opin 26 2010 2339 2346
27. J.B. Bussel, G. Cheng, M.N. Saleh, B. Psaila, L. Kovaleva, B. Meddeb, and et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura N Engl J Med 357 2007 2237 2247
28. G. Cheng, M.N. Saleh, C. Marcher, S. Vasey, B. Mayer, M. Aivado, and et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study Lancet 377 2011 393 402
29. Y. Tomiyama, Y. Miyakawa, S. Okamoto, S. Katsutani, A. Kimura, Y. Okoshi, and et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia J Thromb Haemost 10 2012 799 806
30. E.S. Wang, R.M. Lyons, R.A. Larson, S. Gandhi, D. Liu, C. Matei, and et al. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide J Hematol Oncol 5 2012 71
31. P.L. Greenberg, G. Garcia-Manero, M. Moore, L. Damon, G. Roboz, K. Hu, and et al. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine Leuk Lymph 54 2013 321 328
32. Amgen Clinical Trial Summary: 20050154. Summary report for study: Dose/schedule finding trial of AMG 531 for chemotherapy-induced thrombocytopenia (CIT) in non-small cell lung cancer (NSCLC) 2014 Available at: http://www.amgentrials.com/amgen/trialsummary.aspx?studyid=20050154 [accessed December 2014].
33. E.S. Winer, H. Safran, B. Karaszewska, D.A. Richards, L. Hartner, F. Forget, and et al. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study Cancer Med 2014 10.1002/cam4.326
34. D.J. Kuter The biology of thrombopoietin and thrombopoietin receptor agonists Int J Hematol 98 2013 10 23
35. P. Saini, Y.K. Loke, C. Gamble, D.G. Altman, P.R. Williamson, and J.J. Kirkham Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews BMJ 349 2014 g6501